New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
07:08 EDTQDEL, DGX, ABAX, IDXX, VIVO, EXASLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.
News For IDXX;DGX;EXAS;ABAX;QDEL;VIVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
10:02 EDTIDXXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:12 EDTIDXXWilliam Blair names 21 stocks best positioned for volatile markets
Subscribe for More Information
06:11 EDTIDXXIDEXX downgraded to Market Perform from Outperform at Raymond James
Subscribe for More Information
August 27, 2015
10:00 EDTVIVOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:15 EDTVIVOMeridian Bioscience initiated with a Long-Term Buy at Hilliard Lyons
Subscribe for More Information
August 26, 2015
15:49 EDTEXASExact Sciences says CMS advisors vote to maintain Cologuard reimbursement rate
Subscribe for More Information
14:43 EDTQDELQuidel management to meet with William Blair
Subscribe for More Information
August 24, 2015
08:29 EDTQDELWilliam Blair to hold a field trip
Subscribe for More Information
08:00 EDTEXASExact Sciences price target lowered to $26 from $32 at Canaccord
Canaccord lowered its price target on Exact Sciences to $26 from $32 to reflect dilution of the large secondary offering. The firm maintains its Buy rating on Exact Sciences shares, citing its sales force expansion, payer traction and a high probability of a positive outcome from the USPSTF decision.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use